Last reviewed · How we verify
NCT04762992: HepaGrowth
LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)
Phase 3 trial testing subcutaneous Enoxaparin in Fetal Growth Retardation in 12 participants. Enrolling by invitation.
30 July 2026
Quick facts
| Lead sponsor | Centro Hospitalar de Lisboa Central |
|---|---|
| Phase | Phase 3 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 18 July 2022 |
| Primary completion | 30 July 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across Portugal |
Drugs / interventions tested
- subcutaneous Enoxaparin
- standard of care
Conditions studied
- Fetal Growth Retardation — all drugs for Fetal Growth Retardation →
- Prematurity — all drugs for Prematurity →
- Pre-Eclampsia — all drugs for Pre-Eclampsia →
Sponsor
Centro Hospitalar de Lisboa Central
Who can join
18 and older, female only, with Fetal Growth Retardation or Prematurity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality. Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04762992
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fetal Growth Retardation
Currently open trials in the same condition.
- NCT06952777 — Validation of Sensors for Long-term Non-Invasive Fetal Monitoring · NA · recruiting
- NCT06405360 — DEUX OEUFs: Cracking the Potential of Eggs to Improve Child Growth and Development · NA · active not recruiting
- NCT06096805 — Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR) · recruiting
- NCT06215690 — Evaluation of Anterior Middle Brain Structures With Cerebrovascular Flow in Fetuses With Fetal Growth Restriction · active not recruiting
- NCT06416995 — Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes · recruiting
Other Centro Hospitalar de Lisboa Central trials
Trials by the same sponsor.
- NCT07483424 — Determination of Clinical Phenotypes of Intrauterine Growth Restriction in Term Infants Based on Body Composition · enrolling by invitation
- NCT06830226 — Domperidone on the Composition of Preterm Breastmilk Using a Human Milk Mid-infrared Spectroscopy Analyzer · enrolling by invitation
- NCT06839443 — Deep Learning in the Detection and Prediction of Hydroxychloroquine Maculopathy · recruiting
- NCT06094309 — Effectiveness of Botulinum Toxin in Freezing of Gate in Parkinson's Disease Walking in Parkinson's Disease. · NA · unknown
- NCT06044480 — Effect of Dexamethason on Postimplantation Syndrome After EVAR · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04762992 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centro Hospitalar de Lisboa Central
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04762992.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing